Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH, Conference Calls/ Webcasts

Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference


BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held in Toronto, Ontario from April 25-26, 2023.

Company Presentation Details:
  
Date: Tuesday, April 25, 2023
  
Time:11:00 am Eastern Time (8:00 am Pacific Time)
  
Webcast:Register here
  
Presenter: Ian Mortimer, President and CEO

A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]



These press releases may also interest you

at 07:15
The National Business League, National Medical Association, National Bar Association, and More Announce Collaborative Effort to Empower and Protect Black American Communities
The National Business League (NBL)®, National Medical Association (NMA)®, and National Bar Association (NBA)® are proud to announce a collaborative effort to address critical issues impacting Black communities. This initiative focuses on protecting...

at 07:05
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
Natera, Inc. , a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and...

at 06:58
Global Recombinant Proteins Market Expected to Reach $203.6 Billion by 2029
"According to the latest BCC Research study, the demand for "Global Recombinant Proteins Market" is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through...

at 06:30
Nyxoah Has Signed a ?37.5 Million Loan Facility Agreement with the European Investment Bank
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Has Signed a ?37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium ? July 3, 2024, 12:30pm CET / 6:30am ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)...

at 06:30
Animal health market: A high revenue generating industry with revenue crossing US$ 112.0 billion by 2030 - Analyzed on Horizon Databook by Grand View Research, Inc.
Increasing pet ownership and the trend of treating pets as family members, the rising demand for livestock products due to a growing global population, and the need to manage zoonotic diseases to protect public health are some factors driving the...

at 06:00
Anti-Migrating Agent Market worth $224 million by 2029 - Exclusive Report by MarketsandMarketstm
The report "Anti-Migrating Agent Market by Type (Non-ionic, Anionic, Cationic, Amphoteric), Grades (Technical, Food, Pharmaceutical), Application, Chemistry (Organic, Inorganic), End-Use Industry (Textile, Plastics, Paper), and Region - Global...

More news about Health...


News published on and distributed by: